Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rotigotine transdermal - UCB

Drug Profile

Rotigotine transdermal - UCB

Alternative Names: Leganto; N-0437; N-0923; Neupro; Neupro Patch; Nubrenza; Rotigotine PR2.1.1; Rotigotine PR2.2.1; SPM-962

Latest Information Update: 06 Feb 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Aderis Pharmaceuticals
  • Developer Abbott Laboratories; Andromaco; Otsuka Pharmaceutical; UCB
  • Class Antiparkinsonians; Small molecules; Tetrahydronaphthalenes; Thiophenes
  • Mechanism of Action Dopamine D2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Parkinson's disease; Restless legs syndrome
  • No development reported Fibromyalgia

Most Recent Events

  • 20 Dec 2018 Phase-III clinical trials in Restless legs syndrome (In adolescents) in USA (Transdermal) (NCT03728933)
  • 02 Nov 2018 UCB Pharma plans a phase III trial for Restless Legs Syndrome (In adolescents) in November 2018 (Transdermal) (NCT03728933)
  • 03 Jul 2018 Registered for Parkinson's disease (Adjunctive treatment, Late-stage disease) in China (Transdermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top